Breaking Finance News

Endo Intl (TSE:ENDP) target price raised to $19.00, reported today by Mizuho Securities

Endo Intl (TSE:ENDP) had its target price raised to $19.00 by Mizuho Securities in an issued report announced 05/25/2017. The bumped up target suggests a potential upside of 0.49% from the company's most recent stock price close.

On 2/22/2017, Canaccord released a statement for Endo Intl (TSE:ENDP) bumped up the target price from $0.00 to $14.00 that suggested an upside of 0.06%.

Boasting a price of $12.78, Endo Intl (TSE:ENDP) traded 0.00% even on the day. With the last stock price close up 0.00% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the date range. Endo Intl has recorded a 50-day average of $0.00 and a two hundred day average of $0.00. Volume of trade held steady, with 0 shares of ENDP changing hands on par with the typical 0

Performance Chart

Endo Intl (TSE:ENDP)

With a total market value of $0, Endo Intl has with a one year low of $0.00 and a one year high of $0.00 .

Brief Synopsis About Endo Intl (TSE:ENDP)

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, womenÂ’s health, and cardiovascular disease markets. The companyÂ’s U.S. Branded Pharmaceuticals segment offers pain management products, such as Lidoderm, OPAN ER, Percocet, and Voltare Gel. This segment also provides Supprelin LA for central precocious puberty treatment; XIAFLEX for treating PeyronieÂ’s and DupuytrenÂ’s contracture diseases; Fortesta Gel for hypogonadism treatment; Testim Gel for the treatment of endogenous testosterone; Frova for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; Vantas for the palliative treatment of advanced prostate cancer; Aveed for the treatment of low testosterone; TESTOPEL, a long-acting implantable pellet; and NASCOBAL, a nasal spray. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ’s health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *